摘要
目的探讨合并乙肝病毒(Hepatitis B Virus,HBV)感染对弥漫大B细胞淋巴瘤(Diffuse Large B Cell Lymphoma,DLBCL)患者细胞免疫功能的影响。方法均接受联合免疫化疗治疗的DLBCL患者296例,采用四色流式分析法测定患者化疗前、化疗3个月、化疗6个月、化疗12个月时其外周血CD3+、CD4+、CD8+、CD4+/CD8+水平,分析HBs Ag阳性、HBs Ag阴性患者相关免疫指标的变化情况。结果在化疗后3个月,阳性组患者CD3+水平较化疗前和阴性组均出现显著下降,差异具有统计学意义(P<0.05);在化疗后6个月、12个月时,两组患者CD3+水平并无明显差异(P>0.05);在化疗期间,阳性组患者CD4+水平并无明显变化,但其CD4+/CD8+水平呈持续下降趋势,化疗后3个月、6个月、12个月时均显著低于阴性组,差异具有统计学意义(P<0.05)。结论合并HBV感染易造成DLBCL患者在化疗过程中出现细胞免疫功能下降。
Objective To explore the effect of hepatitis B virus( HBV) infection on cellular immune function in patients with diffuse large B cell lymphoma( DLBCL). Methods 296 patients with DLBCL treated with combined immunotherapy were firstly chosen as the subjects of study. The levels of CD3+,CD4+,CD8+ and CD4+/CD8+ in peripheral blood of the subjects before chemotherapy,3 months,6 months and 12 months after chemotherapy were measured by four-color flow analysis. The changes of the immune parameters related to HBs Ag positive and HBs Ag negative patients were analyzed.Results At 3 months after chemotherapy,the levels of CD3 + in the positive group were lower than those in the negative group and before chemotherapy( P〈0.05). No statistically significant difference was found in CD3+ level between 6 months and 12 months after chemotherapy( P〉0.05). There was no significant change in CD4+ level in the positive group,but the CD4+/CD8+ level continued to decrease after 3 months,6 months and 12 months after chemotherapy. At 3 months,6 months and 12 months after chemotherapy,the levels of CD4 +/CD8 + in the positive group were lower than those in the negative group( P〈0.05). Conclusions HBV infection can lead to the decline of cellular immune function in patients with DLBCL during chemotherapy.
作者
施伦波
赵燕
韩世伟
孙密芬
饶爱华
SHI Lun-bo;ZHAO Yan;HAN Shi-wei;SUN Mi-fen;RAO Ai-hua(Department of Hematology, The People' s Hospital of Fenghua District, Ningbo 315500, China)
出处
《健康研究》
CAS
2018年第2期178-181,共4页
Health Research
关键词
弥漫大B细胞淋巴瘤
乙型肝炎
化疗
细胞免疫
diffuse large B cell lymphoma
hepatitis B
chemotherapy
cellular immunity